Regulatory conditions on Novo Holdings' $16.5 billion Catalent deal fulfilled, companies say

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.